Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
New Nonsteroidal Topical Treatment Options for Atopic Dermatitis
Panelists discuss recent topical atopic dermatitis therapies, which include roflumilast (PDE4 inhibitor, age ≥ 6 years), ruxolitinib (JAK inhibitor, age ≥ 12 years), and tapinarof (hydrocarbon receptor agonist, age ≥ 2 years). Treatment selection considers disease severity, age, affected areas, comorbidities, and previous therapy responses.
EP: 1.Diagnosing and Defining Severity of Atopic Dermatitis
EP: 2.Older Approaches to Topical Treatment of Atopic Dermatitis
Now Viewing
EP: 3.New Nonsteroidal Topical Treatment Options for Atopic Dermatitis
EP: 4.Long-Term Use of Topical Treatments in Atopic Dermatitis
EP: 5.Addressing Itch and Quality of Life for Patients With Atopic Dermatitis
EP: 6.Importance of Patient Education and Multidisciplinary Communication
Video content above is prompted by the following:
- There have been several new topical therapies approved in recent years. Discuss these treatments, how they work to treat atopic dermatitis, as well as an overview of efficacy and safety data.
- Topical roflumilast (0.15% cream): FDA approved for patients 6 years or older
- PDE4 inhibitor; INTEGUMENT-1 and INTEGUMENT-2
- Topical ruxolitinib (1.5% cream): FDA approved for patients 12 years or older
- JAK inhibitor; TRuE-AD1 and TRuE-AD2
- Topical tapinarof (1% cream): FDA approved for patients 2 years or older
- Hydrocarbon receptor agonist; ADORING 1 and ADORING 2
- Topical roflumilast (0.15% cream): FDA approved for patients 6 years or older
- What patient factors do you consider when selecting a treatment option?
- How do you decide among all the available topical treatment options for your patients?
Related Videos
Related Content
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025Article
RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.
